Navigation Links
HealthFrontier Introduces New Innovation in Web-Based Remote Health Monitoring Technology
Date:6/18/2009

Solution featured as part of the Premier healthcare alliance Innovation Celebration

ANAHEIM, Calif., June 18 /PRNewswire/ -- HealthFrontier, Inc., together with its technology partner, et medical devices SpA, Italy, yesterday introduced a new innovation in web-enabled electrocardiogram (ECG) technology. The ecg@home(TM), small enough to fit in the palm of a hand, can record a 10-second ECG rhythm strip without electrode cables by just using the thumbs.

The ecg@home(TM) debuted at the Premier healthcare alliance Annual Breakthroughs Conference and Exhibition in Anaheim, CA. It was one of only 26 products selected for showcase at Premier's inaugural Innovation Celebration, an event to celebrate advances in healthcare while highlighting healthcare industry suppliers committed to innovation and improving patient outcomes.

"The combination of advanced hardware and web-enabled telemedicine allows physicians and hospitals to review ECG reads soon after patients perform the test remotely in their own homes," said Tony Uccello, VP of Product Development at HealthFrontier. "The ecg@home(TM) enables practitioners to provide better, more informed care for their patients without requiring time-consuming office visits. This new focus on portability and connectivity has many companies considering how these innovative technologies can add value to their products and services."

The ecg@home(TM) is powered by an IT backbone known as the Remote Health Monitoring System (RHMS). HealthFrontier's RHMS is a web-enabled software application that automatically receives, stores and forwards incoming ECG scans to a patient's Electronic Medical Record, thus eliminating the need for paper printouts. This innovative technology is certified on Dell systems, ensuring easy and seamless connectivity from patient to physician systems. It will be available for purchase both as a stand alone unit and with Dell hardware t
'/>"/>

SOURCE HealthFrontier, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW
2. Noteworthy Medical Systems Introduces NetPay(TM)
3. Language Technologies Introduces ReadSmart Edition Apps(TM) for the iPhone(TM) and iPod(R) Touch; Unique Apps Improve Ergonomics of Reading while Retaining Look and Design of Print Books
4. CEP America Introduces ER Forum Blog
5. Autism Family Foundation Introduces The Robert J. Keegan Family Center for Autism
6. Clinical Innovations Introduces New Circumcision Device
7. TOPAZ Technologies Introduces Biosafety Software Solution
8. FluxData, Inc. Introduces New Multispectral Camera with Embedded PC104 Computer
9. Versus Introduces Automated, Real-Time Hand Hygiene Compliance Solution
10. Alere Introduces Industrys First 12-month Unlimited Health Coaching Program
11. Nonin Medical Introduces Next-Generation Regional Oximeter at Euroanaesthesia 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 2Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 3Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 4Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 5Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 6Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 7Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 8Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3